Vaccines against multiple subtypes of dengue virus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 5, 2018
Issued Date -
N/A
app pub date -
Mar 14, 2014
filing date -
Mar 15, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.
First Claim
Family
International Classification(s)
- C07H:SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTI....
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF
- A01K:ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; ....
- A61N:ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY;....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully